Not Yet RecruitingPhase 1

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

United States50 participantsStarted 2026-06

Plain-language summary

The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the modern approach to GVHD prevention, GVHD rates have reduced markedly.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Ability to understand and the willingness to provide written informed consent.

Exclusion criteria

✕. Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or
✕. Presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) \>1000 by solid phase immunoassay.
✕Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the recipient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.

What they're measuring

Safety and Feasibility of Early Tacrolimus Discontinuation

Timeframe: Day 0 through Day 180 post-transplant

Trial details

NCT IDNCT07302776

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-02

Contact for this trial

Kelly Chyan

650-625-8130 kchyan@stanford.edu

View on ClinicalTrials.gov More GVHD trials